- Home
- KAVL vs PPBT Comparison
KAVL vs PPBT Comparison
Compare KAVL & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- PPBT
- Stock Information
- Founded
- KAVL 1998
- PPBT 2010
- Country
- KAVL United States
- PPBT Israel
- Employees
- KAVL N/A
- PPBT N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- PPBT Health Care
- Exchange
- KAVL Nasdaq
- PPBT Nasdaq
- Market Cap
- KAVL 7.9M
- PPBT 6.5M
- IPO Year
- KAVL N/A
- PPBT N/A
- Fundamental
- Price
- KAVL $0.60
- PPBT $2.20
- Analyst Decision
- KAVL
- PPBT Strong Buy
- Analyst Count
- KAVL 0
- PPBT 1
- Target Price
- KAVL N/A
- PPBT $33.00
- AVG Volume (30 Days)
- KAVL 56.2K
- PPBT 285.3K
- Earning Date
- KAVL 06-17-2025
- PPBT 05-23-2025
- Dividend Yield
- KAVL N/A
- PPBT N/A
- EPS Growth
- KAVL N/A
- PPBT N/A
- EPS
- KAVL N/A
- PPBT N/A
- Revenue
- KAVL $3,877,695.00
- PPBT N/A
- Revenue This Year
- KAVL N/A
- PPBT N/A
- Revenue Next Year
- KAVL N/A
- PPBT N/A
- P/E Ratio
- KAVL N/A
- PPBT N/A
- Revenue Growth
- KAVL N/A
- PPBT N/A
- 52 Week Low
- KAVL $0.46
- PPBT $2.00
- 52 Week High
- KAVL $8.37
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- KAVL 57.87
- PPBT 35.17
- Support Level
- KAVL $0.59
- PPBT $2.16
- Resistance Level
- KAVL $0.65
- PPBT $2.41
- Average True Range (ATR)
- KAVL 0.04
- PPBT 0.21
- MACD
- KAVL 0.02
- PPBT -0.01
- Stochastic Oscillator
- KAVL 72.34
- PPBT 16.48
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.